0001157523-13-003651.txt : 20130730 0001157523-13-003651.hdr.sgml : 20130730 20130729173254 ACCESSION NUMBER: 0001157523-13-003651 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130725 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20130730 DATE AS OF CHANGE: 20130729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DYAX CORP CENTRAL INDEX KEY: 0000907562 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043053198 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24537 FILM NUMBER: 13993508 BUSINESS ADDRESS: STREET 1: 55 NETWORK DRIVE CITY: BURLINGTON STATE: MA ZIP: 01803-2756 BUSINESS PHONE: 617-250-5769 MAIL ADDRESS: STREET 1: 55 NETWORK DRIVE CITY: BURLINGTON STATE: MA ZIP: 01803-2756 FORMER COMPANY: FORMER CONFORMED NAME: BIOTAGE INC DATE OF NAME CHANGE: 19951117 8-K 1 a50680253.htm DYAX CORP. 8-K a50680253.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  July 25, 2013
 
 
DYAX CORP.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
000-24537
04-3053198
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
55 Network Drive
Burlington, MA  01803
(Address of Principal Executive Offices)  (Zip Code)
 
(617) 225-2500
(Registrant's telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o          Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o          Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o          Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))
 
 
 
 
 
Item 7.01.          Regulation FD Disclosure.
 
On July 25, 2013, Dyax Corp. ("Dyax") received clearance from the U.S. Food and Drug Administration ("FDA") for an Investigational New Drug application ("IND") to allow clinical testing of DX-2930, Dyax's fully human monoclonal antibody inhibitor of plasma kallikrein.   Dyax can now proceed with a Phase 1 trial to evaluate the safety, tolerability and pharmacokinetics of DX-2930 in healthy volunteers and expects to do so in the very near future.

The information in this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Act, except to the extent that Dyax specifically incorporates it by reference.
 
 
Certain information included in this current report is forward-looking in nature within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  This report uses terminology such as “believes,” “plans,” “expects,” “intends” and similar expressions to identify forward-looking statements.  Examples of forward-looking statements in this report include statements about our intention to commence a Phase I trial of DX-2930.  The forward-looking statements in this report are based on our current good faith beliefs; however, actual results may differ due to inaccurate assumptions regarding our ability to initiate, or hire a third party to initiate, such trial in a timely manner.  Consequently, we cannot guarantee that any of the forward-looking statements will prove to be accurate.  The forward-looking statements in this report speak only as of the date of this report.
 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
DYAX CORP.
     
     
       
Dated:       July 29, 2013
By:
/s/George Migausky
  
   
George Migausky,
   
Executive Vice President and
   
Chief Financial Officer